Publications by authors named "Tim Tasker"

Claim this Profile
A
A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's disease.
Pradeep J Nathan, S Babli Millais, Alex Godwood, Odile Dewit, David M Cross, Tim Tasker

Alzheimers Dement (N Y)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M -acetylcholine receptor agonist: A randomized cross-over trial.
Charlotte Bakker, Samantha Prins, Jan Liptrot, Ellen P Hart, Erica S Klaassen, Tim Tasker

Br J Clin Pharmacol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease.
Alastair J H Brown, Sophie J Bradley, Fiona H Marshall, Giles A Brown, Kirstie A Bennett, Tim Tasker

Cell· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Pharmacokinetics of HTL0018318, a Novel M Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects.
Charlotte Bakker, Jasper van der Aart, Geert Labots, Jan Liptrot, David M Cross, Tim Tasker

Drugs R D· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M -receptor partial agonist for the treatment of dementias.
Charlotte Bakker, Tim Tasker, Jan Liptrot, Ellen P Hart, Erica S Klaassen

Br J Clin Pharmacol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study.
Charlotte Bakker, Tim Tasker, Jan Liptrot, Ellen P Hart, Erica S Klaassen

Alzheimers Res Ther· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cholinergic muscarinic M and M receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders.
Daniel Erskine, John-Paul Taylor, Geor Bakker, Alastair J H Brown, Tim Tasker

Drug Discov Today· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of elderly primary insomnia patients with EVT 201 improves sleep initiation, sleep maintenance, and daytime sleepiness.
James K Walsh, Lynette Salkeld, Lisa J Knowles, Tim Tasker, Ian M Hunneyball

Sleep Med· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients.
James K Walsh, Steve Thacker, Lisa J Knowles, Tim Tasker, Ian M Hunneyball

Sleep Med· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis